Kendall v. Odonate Therapeutics, Inc.

District Court, S.D. California·Decided January 18, 2022·No. 3:20-cv-01828·Unknown

Opinion

KEVIN KENDALL, individually and on Case No.: 3:20-cv-01828-H-LL behalf of all others similarly situated, AMENDED ORDER: Plaintiff, v. (1) CERTIFYING CLASS FOR SETTLEMENT PURPOSES; ODONATE THERAPEUTICS, INC., KEVIN C. TANG, MICHAEL HEARNE, (2) PRELIMINARILY APPROVING CLASS SETTLEMENT; Defendants.

(3) APPOINTING CLASS REPRESENTATIVE AND CO- COUNSEL; (4) APPROVING CLASS NOTICE; and (5) SCHEDULING FINAL APPROVAL HEARING [Doc. No. 43.] On December 3, 2022, Plaintiff Kevin Kendall filed an unopposed motion for preliminary approval of class action settlement and directing dissemination of notice to the class. (Doc. No. 43.) On January 3, 2022, Defendants Odonate Therapeutics, Inc., Kevin C. Tang, Michael Hearne, John G. Lemkey (collectively, “Defendants”) filed a notice of non-opposition to Plaintiff’s motion. (Doc. No. 46.) The Court held a hearing on the matter on January 10, 2022. Corey D. Holzer, Jennifer Banner Sobers, and Matthew L. Tuccillo appeared on behalf of Plaintiff. Stephan Ryan Benson Richards appeared on behalf of Defendants. For the following reasons, the Court grants Plaintiff’s motion and sets a schedule for further proceedings. Background I. Factual and Procedural Background This is a securities class action against Odonate Therapeutics, Inc. (“Odonate”) and three of its officers under Section 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rule 10b-5. (Doc. No. 24, SAC ¶¶ 225–41.) The case is brought on behalf of all persons and entities who purchased or otherwise acquired the stock of Odonate between December 7, 2017 and March 25, 2021 (the “Class Period”). (Id. ¶ 217.) Odonate is a pharmaceutical company based in San Diego. (Id. ¶ 2.) Odonate’s single, primary drug candidate is tesetaxel, an orally administered chemotherapy agent developed to treat patients with locally advanced or metastatic breast cancer. (Id. ¶¶ 33–35.) Defendants Tang, Hearne, and Lemkey were officers and collectively the majority shareholder of Odonate during the Class Period. (Id. ¶¶ 1, 3, 19– 21.) In December 2017, Odonate initiated a Phase 3 study of tesetaxel. (Id. 36, 57-59.) Plaintiff alleges that between December 8, 2017 and February 23, 2021, Odonate filed for an Initial Public Offering (“IPO”) with the Securities and Exchange Commission (“SEC”) and held multiple subsequent public offering of its shares in order to raise funds for Odonate’s continued operations and tesetaxel’s study. (Id. ¶¶ 37–38, 188.) Plaintiff alleges that through its IPO and subsequent offerings, Odonate raised $394.6 million in gross proceeds and $369.78 million in net proceeds. (Id. ¶ 39.) Plaintiff alleges Odonate’s value proposition to investors was tesetaxel. (Id. ¶ 36.) Plaintiff alleges that during the Class Period, significant safety concerns regarding tesetaxal arose during the Phase 3 study, which Plaintiff alleges Defendants were aware of but did not disclose to investors or the public. (Id. ¶¶ 5–7, 40.) Plaintiff also alleges that during the class period, Defendants made false and misleading statements containing misrepresentations and omissions regarding the tesetaxel Phase 3 study, patient outcomes and experiences while using tesetaxel, and the likelihood of tesetaxels’ approval by the FDA. (Id. ¶¶ 56–181.) On March 22, 2021, Odonate issued a press release announcing it was discontinuing tesetaxel’s development following feedback from the U.S. Food and Drug Administration (“FDA”) that the clinical data package for tesetaxel was unlikely to support FDA approval. (Id. ¶ 168.) On March 25, 2021, Odonate filed a Form 8-K with the SEC providing more details about Odonate’s discontinuation of tesetaxels’ development and the wind-down of Odonate’s operations. (Id. ¶ 170.) Plaintiff alleges Odonate’s stock price fell dramatically following the press release and Form 8-K filing. (Id. ¶¶ 169, 171.) On September 16, 2020, Plaintiff filed a class action complaint against Defendants. (Doc. No. 1.) On December 14, 2020, the Court granted Plaintiff’s unopposed motion to appoint Plaintiff as Lead Plaintiff and approval of Plaintiff’s selection of counsel. (Doc. No. 11.) On February 16, 2021, Plaintiff filed the first amended class action complaint. (Doc. No. 21.) On April 13, 2021, Plaintiff filed the second amended class action complaint. (Doc. No. 24.) On May 13, 2021, Defendants filed a motion to dismiss Plaintiff’s second amended complaint. (Doc. No. 25.) On August 4, 2021, the Court denied Defendants’ motion to dismiss. (Doc. No. 36.) On September 3, 2021, Defendants filed their answer to Plaintiff’s second amended complaint. (Doc. No. 37.) On September 20, 2021, the parties held a virtual mediation before Michelle Yoshida, Esq. of Phillips ADR Enterprise, but were unable to reach a settlement that day. (Doc. No. 43 at 4.) Over the next three weeks the parties continued negotiations and ultimately came to an agreement to settle the action in principle. (Id.) On October 19, 2021, the parties executed a memorandum of understanding regarding the settlement in principle. (Id.) On October 26, 2021, the parties filed a joint motion to enter a stipulation to stay the proceedings pending settlement. (Doc. No. 39.) On November 3, 2021, the Court granted the parties’ joint motion to stay the proceedings. (Doc. No. 39.) The Court also ordered Plaintiff to file a motion for preliminary approval of the class action settlement on or before January 31, 2022. (Id.) On December 3, 2021, Plaintiff filed the present unopposed motion seeking (1) preliminary approval of the proposed class action settlement; (2) preliminary certification of the settlement class, appointment of Lead Plaintiff as representative of the settlement class, and appointment of Co-Lead Counsel as counsel for the settlement class; (3) approval of the form and manner of giving notice to the class; and (4) a final approval hearing and a schedule for various deadlines. (Doc. No. 43.) II. Proposed Settlement Under the proposed settlement, Defendants will pay the settlement amount of $12,750,000.00. (Doc. No. 43-2, Tuccillo Decl. Ex. 1 ¶¶ 1.32, 2.0 (“Stipulation”).) The settlement will be distributed to class members pro rata in accordance with a plan of allocation that has been designed by Co-Lead Counsel. (Id. ¶ 6.7; Ex. B1 at 6.) Under the plan of allocation, a Recognized Loss amount for each share purchased within the Class Period will be calculated based when the stock was purchased or acquired and, if applicable, sold. (Id.; Ex. B1 at 14–15.) The Recognized Loss is the basis for how the settlement fund will be proportionately allocated to class members. (Id. at 12.) The Recognized Loss is intended to estimate the alleged artificial inflation of the price of Odonate stock at different times during the Class Period due to alleged misrepresentations by Defendants. (Id. at 12.) No distribution will be made to class members who would receive a distribution of less than $10.00. (Id. at 16.) Any remaining funds in the settlement fund after at least six (6) months after the initial distribution will be used first, to pay any amounts mistakenly omitted from the initial disbursement; second, to pay any additional settlement administration fees, costs, and expenses; and third, to make a second distribution to class members who cashed their checks from the initial distribution. (Id. at 17.) None of the funds will revert back to Defendants. (Id. ¶¶ 2.5, 6.8.) The class members will receive payment from the settlement fund after taxes and tax expenses, administration costs, a fee and expenses award to Co-Lead Counsel, and a compensatory award to Lead Plaintiff. (Id. § H; Ex. B1 at 2, 9.) The parties agreed to an attorney fee award of up to 33 1/3% of the settlement amount and reimbursement of up to $100,000.00. (Id. § H; Ex. B1 at 2, 9.) The class representatives service award is $5,000. (Id., Ex. B1 at 2, 9.) The parties also agreed to allocate up to $300,000 to pay for the costs and expenses of t

Free access — add to your briefcase to read the full text and ask questions with AI

Kendall v. Odonate Therapeutics, Inc., (S.D. Cal. 2022).

Kendall v. Odonate Therapeutics, Inc. (Kendall v. Odonate Therapeutics, Inc.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Mullane v. Central Hanover Bank & Trust Co.
339 U.S. 306 (Supreme Court, 1950)
General Telephone Co. of Southwest v. Falcon
457 U.S. 147 (Supreme Court, 1982)
Amchem Products, Inc. v. Windsor
521 U.S. 591 (Supreme Court, 1997)
Philip Rannis v. Peter Recchia
380 F. App'x 646 (Ninth Circuit, 2010)
In Re Bluetooth Headset Products Liability
654 F.3d 935 (Ninth Circuit, 2011)
Staton v. Boeing Co.
327 F.3d 938 (Ninth Circuit, 2003)
Rodriguez v. West Publishing Corp.
563 F.3d 948 (Ninth Circuit, 2009)
In Re Tableware Antitrust Litigation
484 F. Supp. 2d 1078 (N.D. California, 2007)
Muhammed Abdullah v. U.S. Security Associates, Inc.
731 F.3d 952 (Ninth Circuit, 2013)
Hanlon v. Chrysler Corp.
150 F.3d 1011 (Ninth Circuit, 1998)
Alberto v. GMRI, Inc.
252 F.R.D. 652 (E.D. California, 2008)
In re Juniper Networks, Inc. Securities Litigation
264 F.R.D. 584 (N.D. California, 2009)
Class v. City of Seattle
955 F.2d 1268 (Ninth Circuit, 1992)
Ikonen v. Hartz Mountain Corp.
122 F.R.D. 258 (S.D. California, 1988)